PATENT CLAIM ANALYSIS

Application Number: 15875101
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "569000"]

Abstract:
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

Claim (Index 14):
The method of  claim 1 , wherein the prodrug is an ester of treprostinil.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.18919
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14881379', '11603116', '14925084', '14490014', '14710694']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8489137217062779
- 35 USC 102 Novelty (BERT): 0.589191068831331
- Combined Prediction Score: 0.8229414564187831
- Mean Citation Score: 516.17796
- Max Citation Score: 522.5625
- Similarity Product: 437.65564346686006

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test